Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2021 07:00 ET | Source: Altimmune, Inc.

Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™

GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax...
March 22, 2021 07:00 ET | Source: Altimmune, Inc.

Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate

GAITHERSBURG, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced today that it has retained Summit Biosciences, a world-wide...
March 15, 2021 07:00 ET | Source: Altimmune, Inc.

AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection

New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis University Studies Show Complete Protection Against Lethal Challenge and Dramatic Reduction in...
March 12, 2021 01:00 ET | Source: Altimmune, Inc.

Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza

GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its...
March 08, 2021 16:01 ET | Source: Altimmune, Inc.

Altimmune to Present at Upcoming Conferences

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present...
February 25, 2021 07:03 ET | Source: Altimmune, Inc.

Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate

Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers Intranasal administration targets the virus at its point of entry and...
February 25, 2021 07:00 ET | Source: Altimmune, Inc.

Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update

Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced Development of AdCOVID Vectors Targeting Emerging Variants of the SARS-CoV-2 Virus has Begun ALT-801 is Progressing Through...
February 22, 2021 16:30 ET | Source: Altimmune, Inc.

Altimmune To Announce Year End 2020 Financial Results on February 25, 2021

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial...
February 17, 2021 07:02 ET | Source: Altimmune, Inc.

Altimmune Announces FDA Clearance of AdCOVID™ IND Application

GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
December 30, 2020 08:00 ET | Source: Altimmune, Inc.

Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its...